FDC101, a vaccine consisting of mature DCs (mDCs) loaded with autologous RNA and expressing two LAAs (PRAME and WT1), was administered to 20 AML patients in CR1 who were not eligible for allo-HSCT. Here, WT1 is linked to acute myeloid leukemia.